BIOV Stock Overview
Develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bio-View Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.27 |
| 52 Week High | ₪0.37 |
| 52 Week Low | ₪0.22 |
| Beta | 0.37 |
| 11 Month Change | 15.38% |
| 3 Month Change | -0.37% |
| 1 Year Change | -16.43% |
| 33 Year Change | -12.73% |
| 5 Year Change | 0.37% |
| Change since IPO | -62.08% |
Recent News & Updates
Recent updates
Shareholders Will Probably Not Have Any Issues With Bio-View Ltd's (TLV:BIOV) CEO Compensation
Dec 04
Estimating The Intrinsic Value Of Bio-View Ltd (TLV:BIOV)
Feb 14Does BioView Ltd.'s (TLV:BIOV) Weak Fundamentals Mean That The Market Could Correct Its Share Price?
Jan 20What BioView Ltd.'s (TLV:BIOV) 35% Share Price Gain Is Not Telling You
Nov 29
Shareholder Returns
| BIOV | IL Medical Equipment | IL Market | |
|---|---|---|---|
| 7D | 5.5% | 0.08% | 2.7% |
| 1Y | -16.4% | 7.6% | 3.7% |
Return vs Industry: BIOV underperformed the IL Medical Equipment industry which returned 7.6% over the past year.
Return vs Market: BIOV underperformed the IL Market which returned 3.7% over the past year.
Price Volatility
| BIOV volatility | |
|---|---|
| BIOV Average Weekly Movement | 6.8% |
| Medical Equipment Industry Average Movement | 6.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 7.3% |
| 10% least volatile stocks in IL Market | 3.2% |
Stable Share Price: BIOV has not had significant price volatility in the past 3 months.
Volatility Over Time: BIOV's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 33 | Daniel Klain | www.bioview.com |
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company’s products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH and Karyotype samples in real-time; and Allegro Plus, an automatic imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an automated imaging system that supports multiple applications; Encore, an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; Solo Touch Workstation, a stand-alone workstation that streamlines review and analysis of test results away from the microscope; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases.
Bio-View Ltd Fundamentals Summary
| BIOV fundamental statistics | |
|---|---|
| Market cap | ₪35.26m |
| Earnings (TTM) | ₪887.00k |
| Revenue (TTM) | ₪34.34m |
39.8x
P/E Ratio1.0x
P/S RatioIs BIOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOV income statement (TTM) | |
|---|---|
| Revenue | ₪34.34m |
| Cost of Revenue | ₪12.07m |
| Gross Profit | ₪22.28m |
| Other Expenses | ₪21.39m |
| Earnings | ₪887.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0068 |
| Gross Margin | 64.86% |
| Net Profit Margin | 2.58% |
| Debt/Equity Ratio | 0% |
How did BIOV perform over the long term?
See historical performance and comparison